| payload |
{"created_at":"2026-04-17T02:13:18.114 {"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:6e037e2ae6e635ff","evidence_event_ids":["evt_20aaed945a13"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","company":"Trevi Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_be2b9bb754057728","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:38:11.794777+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B5","final_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt","source_event_id":"evt_20aaed945a13","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"68a6f6859835cb81","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 16, 2026","April 15, 2026","November 13, 2025","30 days (option period)","April __, 2026 (delivery estimate; blank in text)","2026-04-17T02:13:18.114675+00:00 (pipeline filing_date field)"],"entities":[{"asset_class":"equity","name":"Trevi Therapeutics, Inc.","relevance":"high","symbol":"TRVI","type":"issuer"},{"asset_class":"equity_market","name":"Nasdaq Global Market","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"regulator","name":"Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only the new filing content is shown.","The number of shares offered is not stated in the provided text (only total dollar amount).","Underwriting discounts/commissions and total proceeds fields are blank in the provided text (shown as $ , $ ).","The expected delivery date is incomplete in the provided text (\"on or about April , 2026\").","No details are provided here about use of proceeds, pricing terms beyond last sale price, or risk factor specifics beyond generic references."],"key_facts":["Form type: 424B5 (Rule 424(b)(5)) for Registration No. 333-291517.","Issuer: Trevi Therapeutics, Inc. (common stock symbol: TRVI).","Offering size disclosed: $150,000,000 of common stock.","Last reported sale price: $14.27 per share on April 15, 2026.","Issuer status: smaller reporting company under SEC rules (reduced disclosure requirements).","Underwriters\u2019 option: 30 days to purchase up to an additional $22,500,000 of shares at the public offering price per share, less underwriting discounts and commissions.","Delivery timing: underwriters expect to deliver shares on or about April __, 2026 (date not filled in provided text).","Document date: preliminary prospectus supplement dated April 16, 2026; prospectus dated November 13, 2025 (as referenced)."],"numeric_claims":[{"label":"Initial offering amount (USD)","value":"150,000,000"},{"label":"Underwriters' option additional amount (USD)","value":"22,500,000"},{"label":"Last reported sale price (USD/share)","value":"14.27"},{"label":"Underwriters' option period (days)","value":"30"}],"primary_claim":"TRVI (Trevi Therapeutics, Inc.) filed a Form 424B5 preliminary prospectus supplement dated April 16, 2026 for an offering of $150,000,000 of common stock, with an underwriters\u2019 30-day option for up to an additional $22,500,000.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Trevi Therapeutics, Inc. filed a Form 424B5 preliminary prospectus supplement for a common stock offering. The filing discloses an initial $150,000,000 offering and an underwriters\u2019 option to purchase up to an additional $22,500,000 of shares.","topics":["SEC filing","prospectus supplement","common stock offering","underwriters' option","Nasdaq listing","smaller reporting company"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 Trevi Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TRVI","tickers":["TRVI"],"title":"TRVI filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-159041.txt"}}... |